Your browser doesn't support javascript.
loading
Therapeutic Strategies For Tay-Sachs Disease.
Picache, Jaqueline A; Zheng, Wei; Chen, Catherine Z.
Afiliação
  • Picache JA; National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD, United States.
  • Zheng W; National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD, United States.
  • Chen CZ; National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD, United States.
Front Pharmacol ; 13: 906647, 2022.
Article em En | MEDLINE | ID: mdl-35865957
Tay-Sachs disease (TSD) is an autosomal recessive disease that features progressive neurodegenerative presentations. It affects one in 100,000 live births. Currently, there is no approved therapy or cure. This review summarizes multiple drug development strategies for TSD, including enzyme replacement therapy, pharmaceutical chaperone therapy, substrate reduction therapy, gene therapy, and hematopoietic stem cell replacement therapy. In vitro and in vivo systems are described to assess the efficacy of the aforementioned therapeutic strategies. Furthermore, we discuss using MALDI mass spectrometry to perform a high throughput screen of compound libraries. This enables discovery of compounds that reduce GM2 and can lead to further development of a TSD therapy.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Front Pharmacol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Front Pharmacol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos